Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and RC48 in HER2-positive Gastric Cancer
NCT05241899Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of fruquintinib and disitamab vedotin in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
fruquintinibdisitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05241899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241899.